Login | Register

Biogen Stops Development Of Drug For Lou Gehrig’s Disease

Biogen Idec has announced that dexpramipexole, an experimental drug for the treatment of amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig's disease, did not pass the Phase 3 clinical trial. The drug was not able to slow the loss of muscular function or lengthen the lifespan of patients with the condition. Therefore, Biogen has decided to cease experimentation on this therapy...

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *